Loading...
XNASENVB
Market cap3mUSD
Dec 24, Last price  
0.31USD
1D
0.00%
1Q
-39.10%
IPO
-100.00%
Name

Enveric Biosciences Inc

Chart & Performance

D1W1MN
XNAS:ENVB chart
P/E
—
P/S
—
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
239.91%
Rev. gr., 5y
20.09%
Revenues
0k
1,105,9231,192,447333,201750,706000000015,976,42236,145,58948,593,71242,998,28039,914,6750000
Net income
0k
P
-157,490-81,515-352,626807,276-143,636-58,544-39,441-33,380-24,621-161-33,644-1,890,758-2,780,686-9,074,813-16,897,516-5,603,975-6,386,945-48,976,896-18,471,3330
CFO
-14m
L-17.80%
343,939-256,568-305,907329,928-150,186-65,041-40,666-30,346-24,850-21,632-43,164-3,671,622-2,703,989-2,740,794-2,565,495-2,453,123-3,888,785-11,457,671-17,146,723-14,094,411
Dividend
Apr 23, 20083.6981 USD/sh
Earnings
Mar 24, 2025

Profile

Enveric Biosciences, Inc., a pharmaceutical company, engages in developing various cannabinoid medicines for cancer care. Its products pipeline includes EV104 for the treatment of osteoarthritis; EVM-101 and EVM-201 for the treatment of cancer related distress; EVM-301 for the treatment of mental health indication; EV102, a cannabinoid cream for topical skin application; and EV101, a cannabinoid and chemotherapy combination therapy. Enveric Biosciences, Inc. is headquartered in Naples, Florida.
URL
https://www.enveric.com/
IPO date
Jul 21, 2009
Employees
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
Cost of revenue
16,512
20,069
25,969
Unusual Expense (Income)
NOPBT
(16,512)
(20,069)
(25,969)
NOPBT Margin
Operating Taxes
29
(1,486)
(7,455)
Tax Rate
NOPAT
(16,541)
(18,583)
(18,515)
Net income
(18,471)
-62.29%
(48,977)
666.83%
Dividends
Dividend yield
Proceeds from repurchase of equity
(1,052)
17,222
21,614
BB yield
37.48%
-572.60%
-98.41%
Debt
Debt current
64
107
Long-term debt
64
245
Deferred revenue
Other long-term liabilities
527
654
Net debt
(2,288)
(17,596)
(17,003)
Cash flow
Cash from operating activities
(14,094)
(17,147)
(11,458)
CAPEX
(5)
(584)
(865)
Cash from investing activities
12
(584)
2,191
Cash from financing activities
(1,343)
18,180
24,900
FCF
(16,307)
(18,853)
(18,966)
Balance
Cash
2,288
17,724
17,356
Long term investments
Excess cash
2,288
17,724
17,356
Stockholders' equity
(97,042)
(78,839)
(60,441)
Invested Capital
98,998
94,459
83,577
ROIC
ROCE
EV
Common stock shares outstanding
2,159
1,446
472
Price
1.30
-37.50%
2.08
-95.53%
46.50
-78.17%
Market cap
2,807
-6.68%
3,008
-86.31%
21,964
-10.39%
EV
519
(13,704)
4,961
EBITDA
(16,104)
(19,634)
(25,288)
EV/EBITDA
0.70
Interest
4
5
10
Interest/NOPBT